Artículos de revistas
Antinociceptive action of hemopressin in experimental hyperalgesia
Registro en:
Peptides. Elsevier Science Inc, v. 26, n. 3, n. 431, n. 436, 2005.
0196-9781
WOS:000226932900011
10.1016/j.peptides.2004.10.026
Autor
Dale, CS
Pagano, RDL
Rioli, V
Hyslop, S
Giorgi, R
Ferro, ES
Institución
Resumen
Endogenous hemorphins, derived from degradation of the beta-chain of hemoglobin, lower arterial blood pressure and exert an antinociceptive action in experimental models of nociception. Hemopressin, derived from the a-chain of hemoglobin, also decreases blood pressure, but its effects on pain have not been studied. In this work, we examined the influence of hemopressin on inflammatory pain. Hemopressin reverted the hyperalgesia induced by either carrageenin or bradykinin when injected concomitantly or 2.5 h after the phlogistic agents. Hemopressin administered systemically also reverted the hyperalgesia induced by carrageenin. Naloxone did not prevent the antinociceptive action of this peptide. These data suggest that hemopressin inhibits peripheral hyperalgesic responses by mechanisms independent of opioid receptor activation. (C) 2004 Elsevier Inc. All rights reserved. 26 3 431 436